secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amneal Pharmaceuticals, Inc. (AMRX)
CIK:        0001723128
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001723128-26-000019
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amneal Q1 2026 net revenue $723M (+4% YoY), GAAP net income $62M, adj. diluted EPS $0.27
--------------------------------------------------------------------------------

- Net revenue $723M (+4% YoY); GAAP net income $62M vs. $12M in Q1 2025; diluted EPS $0.19.
- Adjusted EBITDA $202M (+19% YoY); adjusted diluted EPS $0.27 (+29% vs. $0.21).
- Specialty revenue +23% driven by CREXONT, BREKIYA autoinjector, and UNITHROID; Affordable Medicines +2%.
- AvKARE revenue -4% as government channel growth offset decline in low-margin distribution.
- Affirms previously announced increase in full year 2026 guidance; results matched preliminary numbers from April 22.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1723128/000172312826000019/0001723128-26-000019-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1723128/000172312826000019/amrx-20260507.htm
  HTML page:      https://secwatch.observer/filing/0001723128-26-000019

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer